Tests combined immunotherapy in children with relapsed neuroblastoma
Tests immune-based treatment, with natural killer cells, in children with returning neuroblastoma.
Key facts
- Who runs it
- Hong Kong Children's Hospital
- Where
- Hong Kong, Hong KongSee the site
- Trial code
- Registry title
- Quadruple Immunotherapy for Neuroblastoma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 29 people, planned
- Started
- 1 Jan 2022
- Planned end
- 31 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Natural killer cell
- Dinutuximab beta
- Interleukin-2
- Granulocyte-Macrophage Colony-Stimulating Factor
- Spironolactone
- Naxitamab
- Record updated
- 15 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers whose neuroblastoma has come back or has not responded to treatment. It tests a combination of four immune-based treatments.
- Age
- Up to 18 years.
- Sex
- All sexes can join.
- Disease stage
- Neuroblastoma that has relapsed (come back) or is refractory (did not respond to treatment).
- Biomarker or test result
- An appropriate HLA-haploidentical NK-cell donor must be available.
Main reasons for not taking part
- Pregnant or breastfeeding women
- HIV infection
- People for whom conventional treatment is considered more appropriate
- People unlikely to benefit, for example terminal cancer with life expectancy under 1 month
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- relapsed or refractory neuroblastoma
- Adequate organ function: creatinine clearance ≥40 ml/min/1.73m2, total bilirubin ≤3 times upper limit of normal and ALT ≤500 IU/L, left ventricular shortening fraction ≥25%, and oxygen saturation ≥92% in room air
- Karnofsky or Lansky performance status score ≥50
- Has an appropriate HLA-haploidentical NK-cell donor available
Who cannot take part
- HIV infection
- Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy <1 month
- Pregnant or lactating woman
- Patients for whom conventional treatment is deemed more appropriate
Where in Hong Kong
- Hong Kong Children's HospitalHong Kong, Hong KongContact: Daniel CheukTaking people
About the trial
What the trial wants to find out
This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.
The group in the trial
- InterventionTreatment being tested
Quadruple immunotherapy
Treatment: Natural killer cell, Dinutuximab beta, Interleukin-2, Granulocyte-Macrophage Colony-Stimulating Factor, Spironolactone, and Naxitamab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Quadruple Immunotherapy for Paediatric Patients With Relapsed or Refractory Neuroblastoma
- Plain-language title
- Tests combined immunotherapy in children with relapsed neuroblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 September 2025